TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Exclusion Criteria for both arms:~(1) known adverse reactions to lidocaine; (2) ADHD, ADD, and other inattention disorders; (3) epilepsy, IQ \<80, severe head trauma, birth weight \<2270 grams, and severe autism; (4) treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers; (5) generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness); (6) mouth sores; (7) Ehlers Danlos syndrome, (8) red hair, and (9) current pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- All subjects (Type: EXPERIMENTAL): All subjects get the lidocaine taste test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are at least 6 years of age, and who will not have reached their 18th birthday~* Diagnosis of ADHD and presence of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria A through C for ODD (NOTE: diagnosis for conduct disorder not exclusionary)~* Normal intelligence~* Able to swallow capsules~Exclusion Criteria:~* Weigh less than 20 kilogram (kg) or more than 90 kg at study entry~* Prior treatment with atomoxetine~* History of seizure disorder, suicidal risk, alcohol or drug abuse within the past 3 months~* History of severe allergies or multiple adverse drug reactions~* Cardiovascular disorders: hypertension, unexplained cardiac signs or symptoms, QT (measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle) prolongation , inherited cardiac disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine Fast Titration (Type: EXPERIMENTAL): 0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
- Atomoxetine Slow Titration (Type: EXPERIMENTAL): 0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo daily dose taken orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-75~* Male~* History of chronic kidney disease and cardiorenal syndrome~* Written informed consent~Exclusion Criteria:~* Female~* Acute illness~* Life-threat competitive illness~* Mental disorders~* Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders)~* Need for dialyses~* Hypercalcemia~* Concomitant use of hormone or cytokine medication~* Participation to any drug-investigation during the previous 60 days as checked with VIP check

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paricalcitol treatment (Type: ACTIVE_COMPARATOR): 6-8 μg daily per os (orally) without special diet
- Calcitriol treatment (Type: ACTIVE_COMPARATOR): 2-4 μg daily orally under with dietary restrictions of vitamin D
- Cholecalciferol (Type: ACTIVE_COMPARATOR): alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
- Supplemental (Type: OTHER): intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Documented informed consent from legal guardian~2. 0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort.~3. Clinical diagnosis of superficial cutaneous or mucosal infantile hemangioma (must include all of the following):~   1. Superficial lesion in the dermis~  2. Thin \<2 mm in thickness~  3. Small \>=5 cm at its longest dimension and \<=10cm2~  4. Involves skin or keratinized mucosa~Exclusion Criteria~1. History of previous treatment with any pharmacologic or laser therapy for IH~2. Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot (TOF), hypertension, reactive airways disease)~3. IH that requires systemic therapy (defined by dynamic complication scale \>3)~4. IH of the non-keratinized mucosa~5. Infants with more than one hemangioma that requires therapy~6. Hemodynamically significant cardiovascular disease, as determined by the investigator~7. Known allergy to beta blockers or vehicle~8. Heart rate \<100 beats per minute at screening visit~9. Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block~10. History of Reactive Airways Disease (RAD)~11. Any condition which would make the participant, in the opinion of the investigator unsuitable for the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 84 Days
- Healthy Volunteers: f

Study Arms:
- 0.25% Timolol Treatment (Type: EXPERIMENTAL): Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
- 0.5% Timolol Treatment (Type: EXPERIMENTAL): Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
- Non-Intervention Group (Type: NO_INTERVENTION): Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.~* For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.~* The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.~Exclusion Criteria:~* Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.

- Gender: None
- Minimum Age: 30 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (Type: EXPERIMENTAL): Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL.~Participants will receive LCIG until it is commercially available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years or older at the time of signing informed consent~* Insulin-naïve subjects diagnosed with type 2 diabetes and on stable diabetes treatment with metformin or metformin and SU (metformin 1500 mg or higher or maximum tolerated dose and SU half of maximum allowed dose according to national label or higher) for at least 90 days before screening. Stable is defined as unchanged medication and unchanged dose~* HbA1c 7.0 - 10.0% (53 - 86 mmol/mol) both inclusive~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or of childbearing potential not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period~* Any disorder which, in the opinion of the Investigator might jeopardise subject's safety or compliance with the protocol~* Treatment with any glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term treatment (7 days or less in total) with insulin in connection with intercurrent illness~* History of chronic or idiopathic acute pancreatitis~* Screening calcitonin value greater than or equal to 50 ng/L~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome 2~* Severe renal impairment defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m\^2 per modification of diet in renal disease (MDRD) formula (4 variable version)~* Acute coronary or cerebrovascular event within 90 days before randomisation~* Heart failure, New York Heart Association Class IV~* Known proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator~* Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)~* Mental inability, unwillingness or language barrier precluding adequate understanding of or compliance with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0.5 mg/week (Type: EXPERIMENTAL): None
- Semaglutide 1.0 mg/week (Type: EXPERIMENTAL): None
- Insulin glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years~* Patients with Spondylarthropathies according ASAS group criteria.~* Patients under treatment with anti-TNF therapy (infliximab, adalimumab, etanercept, golimumab) who present established clinical remission~* Patients to give their informed consent to participate in the study~Exclusion Criteria:~* Patients with secondary Spondylarthropathies~* Patients with Spondylarthropathies and predominantly clinical of peripheral arthritis which receive anti-TNF therapy by peripheral symp tons.~* Patients with Spondylarthropathies and other associated diseases that hinders or modify the clinical evaluation of the patient (fibromyalgia, chronic inflammatory disorders...)~* Patients with bowel inflammatory disease~* Patients under chronic therapy with anti-TNF therapy who received the patterns of reduction that will be explored in the experimental group, or low doses or most spaced that those in the experimental group before study inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced doses of anti-TNF (Type: EXPERIMENTAL): Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
- Stable doses of anti-TNF (Type: ACTIVE_COMPARATOR): Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Infants will be eligible for the DANCE trial if they have a gestational age \> 36 weeks by best obstetric estimate, are \< 12 hours old and have evidence of moderate-severe acute perinatal HIE. Eligibility will also include criteria presently used in the NICU to initiate hypothermia:~1. \< 6 hours after birth~2. History of an acute perinatal event (abruption, cord prolapsed, severe fetal heart rate abnormality)~3. Severe fetal or early (\< 1 hour age) neonatal acidosis: arterial pH ≤ 7.0 or a base deficit ≥ 16m mEq/ L~4. If a blood gas is not available or a blood gas at \<1 hour of age has a pH between 7.01 and 7.15, or a base deficit is between 10 and 15.9 mEq/L, additional criteria will be required:~   * acute perinatal event AND~  * either a 10-min Apgar score ≤ 5 or assisted ventilation initiated at birth and continued for at least 10 minutes.~Exclusion Criteria:~1. Major congenital and/or chromosomal abnormalities~2. Prenatal diagnosis of brain abnormality or hydrocephalus~3. Severe growth restriction (\< 1800g)~4. Central venous hematocrit \> 65%, platelet count \> 600,000/dL, and/or neutropenia (ANC \< 500 µL)~5. Maternal history of major vascular thrombosis or multiple fetal losses (\> 3 spontaneous abortions)~6. ECMO~7. Infant judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- High dose Darbepoetin alfa (Type: ACTIVE_COMPARATOR): 10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
- Low dose Darbepoetin alfa (Type: ACTIVE_COMPARATOR): 2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* 1- to 3-vessel coronary artery disease (CAD)~* Stable angina pectoris~* At least 1 stenotic lesion suitable for PCI~* No Q-wave myocardial infarction in the area undergoing CFI measurement~* Written informed consent to participate in the study~Exclusion Criteria:~* Patients admitted as emergencies~* Acute myocardial infarction~* Unstable CAD~* CAD treated best by CABG~* Patients with overt neoplastic disease~* Patients with diabetic retinopathy~* Liver or kidney disease~* Pre-menopausal women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nilotinib in Cerebellar Ataxia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed as chronic cerebellar ataxia~* Confirmed as spinocerebellar ataxia by gene test~Exclusion Criteria:~* Laboratory abnormalities that could interfere with the proper use of Nilotinib QTc interval \>450ms on initial electrocardiograph, Hb \<8.0, WBC\<2000, ANC \<1600, PLT \<140,000, AST \>200, ALT\>200, ALP\>575, Positive HIV serology, active hepatitis B~* Unstable mental or physical status that could interfere with precise evaluation and proper management of SCA Heart failure (NYHA Grade III or IV), history of major heart disease Pregnancy, on breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nilotinib group (Type: EXPERIMENTAL): Patients with SCA and taking nilotinib treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age at the time of enrollment is:~   * 18 through 55 years (before the fifty sixth birthday) for Group 1.~  * 3 through 5 years (before the sixth birthday) for Group 2.~  * 42 to 98 days for Group 3.~2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* Previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination with pneumococcal vaccine.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Adults aged 18 through 55 years (before the fifty sixth birthday)
- Group 2 (Type: EXPERIMENTAL): Children aged 3 through 5 years (before the sixth birthday)
- Group 3 (Type: EXPERIMENTAL): Infants aged approximately 2 months (42 to 98 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete